Select Publications
Journal articles
2024, 'Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML', Blood, 144, pp. 84 - 98, http://dx.doi.org/10.1182/blood.2024024072
,2024, 'Abstract 1080: Using genome-wide CRISPR screening to develop novel combination therapies for high-risk Ewing’s sarcoma', Cancer Research, 84, pp. 1080 - 1080, http://dx.doi.org/10.1158/1538-7445.am2024-1080
,2024, 'Abstract 4599: A novel small molecule inhibitor targeting MYC oncogenic signaling as an enhancer of HDAC inhibitors for the treatment of high-risk medulloblastoma', Cancer Research, 84, pp. 4599 - 4599, http://dx.doi.org/10.1158/1538-7445.am2024-4599
,2024, 'MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression', Oncogene, 43, pp. 363 - 377, http://dx.doi.org/10.1038/s41388-023-02897-y
,2023, 'Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma', International Journal of Molecular Sciences, 24, http://dx.doi.org/10.3390/ijms242115571
,2023, 'Pyrimido[1,2-a]benzimidazoles as inhibitors of oncoproteins ubiquitin specific protease 5 and MYCN in the childhood cancer neuroblastoma', Bioorganic Chemistry, 136, http://dx.doi.org/10.1016/j.bioorg.2023.106462
,2023, 'Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface', Cancers, 15, http://dx.doi.org/10.3390/cancers15061822
,2022, 'Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectory', Cell Reports, 41, http://dx.doi.org/10.1016/j.celrep.2022.111455
,2022, 'The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression', Frontiers in Oncology, 12, pp. 863329, http://dx.doi.org/10.3389/fonc.2022.863329
,2022, 'Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma', International Journal of Cancer, 152, pp. 1399 - 1413, http://dx.doi.org/10.1002/ijc.34349
,2021, 'An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability', Nature Communications, 12, pp. 1881, http://dx.doi.org/10.1038/s41467-021-22143-x
,2021, 'Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia', Nature Communications, 12, pp. 4164, http://dx.doi.org/10.1038/s41467-021-24442-9
,2021, 'Meis2 is an adrenergic core regulatory transcription factor involved in early initiation of th‐mycn‐driven neuroblastoma formation', Cancers, 13, http://dx.doi.org/10.3390/cancers13194783
,2021, 'Synthesis and characterisation of novel tricyclic and tetracyclic furoindoles: Biological evaluation as SAHA enhancer against neuroblastoma and breast cancer cells', Molecules, 26, http://dx.doi.org/10.3390/molecules26195745
,2021, 'A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma', Oncogene, 40, pp. 2367 - 2381, http://dx.doi.org/10.1038/s41388-021-01712-w
,2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044
,2020, 'Synthesis of a Novel Library of 1-Substituted Pyrido[1,2- a ]benzimidazoles', Australian Journal of Chemistry, 73, pp. 1208 - 1218, http://dx.doi.org/10.1071/CH20173
,2020, 'Withaferin A activates TRIM16 for its anti-cancer activity in melanoma', Scientific Reports, 10, pp. 19724, http://dx.doi.org/10.1038/s41598-020-76722-x
,2020, 'A structural view of PA2G4 isoforms with opposing functions in cancer', Journal of Biological Chemistry, 295, pp. 16100 - 16112, http://dx.doi.org/10.1074/jbc.REV120.014293
,2020, 'Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma', International Journal of Cancer, 147, pp. 1928 - 1938, http://dx.doi.org/10.1002/ijc.32936
,2020, 'CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo', Experimental Cell Research, 388, http://dx.doi.org/10.1016/j.yexcr.2020.111850
,2020, 'Synthesis, characterization and biological evaluation of novel dihydropyranoindoles improving the anticancer effects of HDAC inhibitors', Molecules, 25, pp. 1377, http://dx.doi.org/10.3390/molecules25061377
,2019, 'JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma', Nature Communications, 10, pp. 3319, http://dx.doi.org/10.1038/s41467-019-11132-w
,2019, 'The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35', Nature Communications, 10, pp. 5026, http://dx.doi.org/10.1038/s41467-019-12971-3
,2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112
,2019, 'Drugging the Undruggable: Inhibiting MYCN Signalling', The 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery, pp. 98 - 98, http://dx.doi.org/10.3390/proceedings2019022098
,2019, 'Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis', Journal of Cancer Research and Clinical Oncology, 145, pp. 2241 - 2250, http://dx.doi.org/10.1007/s00432-019-02981-5
,2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, 11, http://dx.doi.org/10.1126/scitranslmed.aau1099
,2019, 'Increase in DNA damage by MYCN knockdown through regulating nucleosome organization and chromatin state in neuroblastoma', Frontiers in Genetics, 10, pp. 684, http://dx.doi.org/10.3389/fgene.2019.00684
,2018, 'Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN', Cancer Research, 78, pp. 3122 - 3134, http://dx.doi.org/10.1158/0008-5472.CAN-17-3034
,2017, 'The regulatory role of long noncoding RNAs in cancer', Cancer Letters, 391, pp. 12 - 19, http://dx.doi.org/10.1016/j.canlet.2017.01.010
,2016, 'A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner', Oncotarget, 7, pp. 52166 - 52178, http://dx.doi.org/10.18632/oncotarget.10700
,2016, 'Synthesis, characterization and anti-cancer activity of hydrazide derivatives incorporating a quinoline moiety', Molecules, 21, pp. 916, http://dx.doi.org/10.3390/molecules21070916
,2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004
,2016, 'High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients', Cancer Letters, 374, pp. 315 - 323, http://dx.doi.org/10.1016/j.canlet.2016.02.021
,2016, 'MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma', Oncotarget, 7, pp. 66344 - 66359, http://dx.doi.org/10.18632/oncotarget.11662
,2016, 'MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4', Oncotarget, 7, pp. 54937 - 54951, http://dx.doi.org/10.18632/oncotarget.10709
,2016, 'The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs', Oncotarget, 7, pp. 79217 - 79232, http://dx.doi.org/10.18632/oncotarget.12640
,2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675
,2016, 'Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', European Journal of Cancer, 61, pp. S7 - S7, http://dx.doi.org/10.1016/s0959-8049(16)61016-x
,2015, 'Combination therapies improve the anticancer activities of retinoids in neuroblastoma', World Journal of Clinical Oncology, 6, pp. 212 - 215, http://dx.doi.org/10.5306/wjco.v6.i6.212
,2015, 'Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma', Science Translational Medicine, 7, pp. 312ra176, http://dx.doi.org/10.1126/scitranslmed.aab1803
,2015, 'MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma', Cancer Letters, 366, pp. 123 - 132, http://dx.doi.org/10.1016/j.canlet.2015.06.015
,2015, 'Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma', Molecular Oncology, 9, pp. 1484 - 1500, http://dx.doi.org/10.1016/j.molonc.2015.04.005
,2015, 'Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: Implications for targeted treatment', Clinical Cancer Research, 21, pp. 3327 - 3339, http://dx.doi.org/10.1158/1078-0432.CCR-14-2024
,2015, 'Erratum: Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression (Journal of the National Cancer Institute (2014) 106:7 (dju113) DOI: 10.1093/jnci/dju113)', Journal of the National Cancer Institute, 107, http://dx.doi.org/10.1093/jnci/dju359
,2015, 'MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation', Oncotarget, 6, pp. 5204 - 5216, http://dx.doi.org/10.18632/oncotarget.2477
,2015, 'ChemInform Abstract: Synthesis of Symmetrical and Unsymmetrical Diindolylmethanes via Acid‐Catalyzed Electrophilic Substitution Reactions.', ChemInform, 46, http://dx.doi.org/10.1002/chin.201510146
,2015, 'MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma', Molecular and Cellular Pediatrics, 2, pp. A13 - A13, http://dx.doi.org/10.1186/2194-7791-2-s1-a13
,2014, 'Effects of a Novel Long Noncoding RNA, lncUSMycN, on N-Myc Expression and Neuroblastoma Progression', Journal of the National Cancer Institute, 106, pp. dju113, http://dx.doi.org/10.1093/jnci/dju113
,